HEALTH ECONOMICS BLOG - Trends, Politics, Opinions etc. in biotech & pharma industry

Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf

5.26.2014

Guidelines for payment by results in Catalunya

Dear All,

CatSalut has published a first version of guidelines for the implementation of payment by results schemes for pharmaceuticals.

http://www20.gencat.cat/docs/salut/Minisite/catsalut/Proveidors_professionals/medicaments_farmacia/Acords_Risc_Compartit/Guia_EPR_castellano_1.0.pdf

Regards
Ulf

HEALTH ECONOMICS BLOG - Trends, Politics, Opinions etc. in biotech & pharma industry

5.26.2014

Guidelines for payment by results in Catalunya

No comments:

Post a Comment